Merck & Co., Inc.
GlaxoSmithKline plc
Tesaro, Inc.
Helsinn Group
F. Hoffmann-La Roche Ltd.
Heron Therapeutics, Inc.
Dr. Reddys Laboratories Ltd.
Acacia Pharma
Sun Pharmaceutical Industry Ltd.
Otsuka Holdings Co., Ltd.
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING DRUGS INDUSTRY
2.1 Summary about Chemotherapy-Induced Nausea and Vomiting Drugs Industry
2.2 Chemotherapy-Induced Nausea and Vomiting Drugs Market Trends
2.2.1 Chemotherapy-Induced Nausea and Vomiting Drugs Production & Consumption Trends
2.2.2 Chemotherapy-Induced Nausea and Vomiting Drugs Demand Structure Trends
2.3 Chemotherapy-Induced Nausea and Vomiting Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Existing Drugs
4.2.2 Akynzeo (Netupitant-Palonosetron FDC)
4.2.3 Aloxi (Palonosetron)
4.2.4 Emend (Aprepitant)
4.2.5 Kytril Generic (Granisetron)
4.2.6 Zofran Generic (Ondansetron)
4.2.7 Pipeline Drugs
4.2.8 SUSTOL (Granisetron Injection extended release)
4.2.9 Rolapitant
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Serotonin Receptor Antagonists
4.3.2 NK1 Receptor Antagonists
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Existing Drugs
5.2.2 Akynzeo (Netupitant-Palonosetron FDC)
5.2.3 Aloxi (Palonosetron)
5.2.4 Emend (Aprepitant)
5.2.5 Kytril Generic (Granisetron)
5.2.6 Zofran Generic (Ondansetron)
5.2.7 Pipeline Drugs
5.2.8 SUSTOL (Granisetron Injection extended release)
5.2.9 Rolapitant
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Serotonin Receptor Antagonists
5.3.2 NK1 Receptor Antagonists
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Existing Drugs
6.2.2 Akynzeo (Netupitant-Palonosetron FDC)
6.2.3 Aloxi (Palonosetron)
6.2.4 Emend (Aprepitant)
6.2.5 Kytril Generic (Granisetron)
6.2.6 Zofran Generic (Ondansetron)
6.2.7 Pipeline Drugs
6.2.8 SUSTOL (Granisetron Injection extended release)
6.2.9 Rolapitant
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Serotonin Receptor Antagonists
6.3.2 NK1 Receptor Antagonists
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Existing Drugs
7.2.2 Akynzeo (Netupitant-Palonosetron FDC)
7.2.3 Aloxi (Palonosetron)
7.2.4 Emend (Aprepitant)
7.2.5 Kytril Generic (Granisetron)
7.2.6 Zofran Generic (Ondansetron)
7.2.7 Pipeline Drugs
7.2.8 SUSTOL (Granisetron Injection extended release)
7.2.9 Rolapitant
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Serotonin Receptor Antagonists
7.3.2 NK1 Receptor Antagonists
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Existing Drugs
8.2.2 Akynzeo (Netupitant-Palonosetron FDC)
8.2.3 Aloxi (Palonosetron)
8.2.4 Emend (Aprepitant)
8.2.5 Kytril Generic (Granisetron)
8.2.6 Zofran Generic (Ondansetron)
8.2.7 Pipeline Drugs
8.2.8 SUSTOL (Granisetron Injection extended release)
8.2.9 Rolapitant
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Serotonin Receptor Antagonists
8.3.2 NK1 Receptor Antagonists
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Existing Drugs
9.2.2 Akynzeo (Netupitant-Palonosetron FDC)
9.2.3 Aloxi (Palonosetron)
9.2.4 Emend (Aprepitant)
9.2.5 Kytril Generic (Granisetron)
9.2.6 Zofran Generic (Ondansetron)
9.2.7 Pipeline Drugs
9.2.8 SUSTOL (Granisetron Injection extended release)
9.2.9 Rolapitant
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Serotonin Receptor Antagonists
9.3.2 NK1 Receptor Antagonists
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Merck & Co., Inc.
10.1.2 GlaxoSmithKline plc
10.1.3 Tesaro, Inc.
10.1.4 Helsinn Group
10.1.5 F. Hoffmann-La Roche Ltd.
10.1.6 Heron Therapeutics, Inc.
10.1.7 Dr. Reddys Laboratories Ltd.
10.1.8 Acacia Pharma
10.1.9 Sun Pharmaceutical Industry Ltd.
10.1.10 Otsuka Holdings Co., Ltd.
10.2 Chemotherapy-Induced Nausea and Vomiting Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Merck & Co., Inc.
10.2.2 GlaxoSmithKline plc
10.2.3 Tesaro, Inc.
10.2.4 Helsinn Group
10.2.5 F. Hoffmann-La Roche Ltd.
10.2.6 Heron Therapeutics, Inc.
10.2.7 Dr. Reddys Laboratories Ltd.
10.2.8 Acacia Pharma
10.2.9 Sun Pharmaceutical Industry Ltd.
10.2.10 Otsuka Holdings Co., Ltd.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
